The Power of Partnership in CMT Gene Therapy Research

Video

Susan Ruediger, founder and chief mission officer, CMT Research Foundation, discussed the origins of the CMTRF.

“When my partner and I started the research foundation in 2018, we knew that there was opportunity for us to bring more money, partners, investigators, efforts, and more biotechs and pharma into the CMT space. We knew that if we organized our effort, that there would be an opportunity for us to do that.”

The CMT Research Foundation (CMTRF)’s mission is to help researchers find treatments for Charcot-Marie-Tooth disease (CMT). The foundation funds promising projects, including cell and gene therapy approaches, to address unmet needs in CMT.

In line with their goal, the CMTRF recently signed an agreement with Nationwide Children’s Hospital and awarded a $500,000 grant to Afrooz Rashnonejad, PhD, principal investigator, Nationwide and Assistant Professor, Department of Pediatrics, Ohio State University. Rashnonejad’s research is taking a knock down and replace approach to silencing the mutated MPZ gene and replacing it with a functioning gene.

CGTLive spoke with Susan Ruediger, founder and chief mission officer, CMT Research Foundation, to learn more about the research foundation and its origins. She discussed the importance of partnering between organizations, academia, and industry as well as an early partnership with DTx Pharma that demonstrated the power of partnering.

REFERENCE
CMT Research Foundation Awards Grant to Nationwide Children’s Hospital’s Dr. Afrooz Rashnonejad to Develop Gene Therapy to Cure or Alleviate CMT1B. News release. CMTRF. July 18, 2022. https://cmtrf.org/nationwide-childrens-hospital-cmt1b-press-release/
Recent Videos
Steve Kanner, PhD, the chief scientific officer of Caribou Biosciences
David Dimmock, MBBS, on AI-Guided ASO Development for Ultra-Rare Diseases
Manali Kamdar, MD, on The Importance of Bringing Liso-Cel to Earlier Lines of Lymphoma Treatment
Subhash Tripathi, PhD, on Generating In Vivo CARs With A2-CAR-CISC EngTreg Cells
Luke Roberts, MBBS, PhD, on Challenges in Developing Gene Therapy for Heart Failure
Steve Kanner, PhD, the chief scientific officer of Caribou Biosciences
Paul Y. Song, MD, the chairman and chief executive officer of NKGen
Lisa Nieland on Slowing Tumor Growth in Glioblastoma With Novel AAV Therapy
Manali Kamdar, MD, on Acclimating to Routine CAR T Practice in the Field
Paul Y. Song, MD, the chairman and chief executive officer of NKGen
© 2024 MJH Life Sciences

All rights reserved.